Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Merck KGaA, Pfizer’s immuno-drug shown to alleviate kidney cancer

Written by: | no-reply@reuters.com | Dated: Tuesday, September 11th, 2018

 

FRANKFURT (Reuters) – Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.

The drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.

The trial will continue to show whether Bavencio plus Inlyta also prolongs patients’ lives.

While the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.

 

Reporting by Ludwig Burger; Editing by Maria Sheahan

 

Reuters source:

https://www.reuters.com/article/us-merck-kidney-cancer/merck-kgaa-pfizers-immuno-drug-shown-to-alleviate-kidney-cancer-idUSKCN1LR1IY

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom